Hicks D - Search Results

1

GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.

Edelman MJ, Feliciano J, Yue B, Bejarano P, Ioffe O, Reisman D, Hawkins D, Gai Q, Hicks D, Serrero G. Edelman MJ, et al. Among authors: hicks d. Hum Pathol. 2014 Sep;45(9):1893-9. doi: 10.1016/j.humpath.2014.05.011. Epub 2014 Jun 5. Hum Pathol. 2014. PMID: 25033727 Free PMC article.

2

Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.

Serrero G, Hawkins DM, Bejarano PA, Ioffe O, Tkaczuk KR, Elliott RE, Head JF, Phillips J, Godwin AK, Weaver J, Hicks D, Yue B. Serrero G, et al. Among authors: hicks d. Diagn Pathol. 2016 Aug 8;11(1):71. doi: 10.1186/s13000-016-0520-4. Diagn Pathol. 2016. PMID: 27501955 Free PMC article.

3

Measurement of Circulating Progranulin (PGRN/GP88/GEP) by Enzyme-Linked Immunosorbent Assay and Application in Human Diseases.

Serrero G, Hicks D. Serrero G, et al. Among authors: hicks d. Methods Mol Biol. 2018;1806:95-105. doi: 10.1007/978-1-4939-8559-3_7. Methods Mol Biol. 2018. PMID: 29956271

4

Immunohistochemical Detection of Progranulin (PGRN/GP88/GEP) in Tumor Tissues as a Cancer Prognostic Biomarker.

Serrero G, Hicks D. Serrero G, et al. Among authors: hicks d. Methods Mol Biol. 2018;1806:107-120. doi: 10.1007/978-1-4939-8559-3_8. Methods Mol Biol. 2018. PMID: 29956272

5

Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.

Tkaczuk KHR, Hawkins D, Yue B, Hicks D, Tait N, Serrero G. Tkaczuk KHR, et al. Among authors: hicks d. Clin Breast Cancer. 2020 Jun;20(3):220-227. doi: 10.1016/j.clbc.2019.11.010. Epub 2019 Dec 5. Clin Breast Cancer. 2020. PMID: 31928925 Free PMC article.

6

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival.

Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, Hicks D, Yue B, Fornara P, Wullich B, Taubert H, Wach S, Lieb V. Greither T, et al. Among authors: hicks d. Cancer Manag Res. 2018 Oct 5;10:4173-4180. doi: 10.2147/CMAR.S172069. eCollection 2018. Cancer Manag Res. 2018. PMID: 30323673 Free PMC article.

7

p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?

Wang X, Stolla M, Ring BZ, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG. Wang X, et al. Hum Pathol. 2016 Sep;55:196-201. doi: 10.1016/j.humpath.2016.05.011. Epub 2016 May 28. Hum Pathol. 2016. PMID: 27246177

8

p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.

Wang X, El-Halaby AA, Zhang H, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG. Wang X, et al. Hum Pathol. 2017 Oct;68:22-25. doi: 10.1016/j.humpath.2017.04.007. Epub 2017 Apr 21. Hum Pathol. 2017. PMID: 28438622

9

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.

Hicks DG, Tubbs RR. Hicks DG, et al. Hum Pathol. 2005 Mar;36(3):250-61. doi: 10.1016/j.humpath.2004.11.010. Hum Pathol. 2005. PMID: 15791569 Review.

10

GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.

Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, Netto GJ. Miyamoto H, et al. Among authors: hicks dg. Hum Pathol. 2012 Nov;43(11):2033-40. doi: 10.1016/j.humpath.2012.02.011. Epub 2012 May 18. Hum Pathol. 2012. PMID: 22607700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

963 results

Search Page